Contract research organisation (CRO) Novotech has signed a memorandum of understanding (MOU) with Wonju Severance Christian Hospital, aiming to boost clinical trials in South Korea.
The initiative marks a step towards enhancing research capabilities and improving patient care within the region.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Leveraging Novotech’s clinical trial management “expertise” with the research capabilities of the hospital, the partnership is focused on the development of new therapeutics while improving clinical trial quality.
Through their combined expertise, the two entities are poised to introduce advancements in clinical trials and medical services.
Wonju Severance Christian Hospital president Young Uh said: “I am pleased to establish our first official partnership agreement with a globally reputable CRO like Novotech.
“We are excited to work together with Novotech to further elevate our research and clinical services.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataNovotech Asia-Pacific managing director Dr Yooni Kim said: “Collaboration with outstanding investigators is vital to the success of clinical trials.
“We look forward to working with the talented research team at Wonju Severance Christian Hospital to drive global clinical trials. We also hope this partnership will help extend clinical trial opportunities to a good-quality hospital beyond Seoul to other regions, contributing positively to local communities for patients.”
Established in 1997, Novotech partners with biotech companies to expedite the development of therapeutics. The company offers a wide array of services, including Phase I facilities, laboratories, drug development consulting, and regulatory guidance.
Having managed more than 5,000 clinical projects, ranging from Phase I to Phase IV trials and bioequivalence studies, Novotech has a presence in 34 office locations.
